|
gptkbp:instanceOf
|
pharmaceutical drug
|
|
gptkbp:activeDuring
|
gptkb:parathyroid_hormone
|
|
gptkbp:administrativeDivision
|
daily
|
|
gptkbp:analyzes
|
statistical analysis
investigational drug
IND_application_submitted
|
|
gptkbp:clinicalTrials
|
gptkb:OPKO_Health
gptkb:Canada
gptkb:United_States
Europe
pending
Phase 3
Phase 2b
randomized controlled trial
NCT number assigned
|
|
gptkbp:collaborations
|
various research institutions
|
|
gptkbp:collection
|
clinical assessments
|
|
gptkbp:contraindication
|
under investigation
|
|
gptkbp:developedBy
|
gptkb:OPKO_Health
|
|
gptkbp:dosageForm
|
injection
|
|
gptkbp:evaluates
|
under investigation
|
|
gptkbp:formulation
|
injectable solution
|
|
gptkbp:future_plans
|
Phase 2
|
|
gptkbp:healthcare
|
ongoing
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
OPKO 3300
|
|
gptkbp:includes
|
adults with hypoparathyroidism
history of certain cancers
|
|
gptkbp:mandates
|
hypoparathyroidism
|
|
gptkbp:manufacturer
|
gptkb:OPKO_Health,_Inc.
|
|
gptkbp:market
|
high
|
|
gptkbp:marketedAs
|
not yet marketed
|
|
gptkbp:patentExpiration
|
2028
|
|
gptkbp:patentStatus
|
patented
|
|
gptkbp:primaryMission
|
safety and efficacy
|
|
gptkbp:productionCompany
|
in development
|
|
gptkbp:publications
|
results to be published
|
|
gptkbp:regulatoryCompliance
|
not yet approved
|
|
gptkbp:research
|
clinical research
funded_by_OPKO_Health
|
|
gptkbp:research_areas
|
hormone replacement therapy
|
|
gptkbp:researchAreas
|
ongoing
|
|
gptkbp:researchField
|
endocrinology
|
|
gptkbp:researchInterest
|
obtained
|
|
gptkbp:route
|
subcutaneous
|
|
gptkbp:safetyFeatures
|
under investigation
|
|
gptkbp:secondaryMission
|
quality of life
|
|
gptkbp:status
|
clinical trial
|
|
gptkbp:targetAudience
|
gptkb:PTH_receptor
|
|
gptkbp:targets
|
adults
hypoparathyroidism
|
|
gptkbp:triggerType
|
replaces parathyroid hormone
|
|
gptkbp:usedFor
|
treatment of hypoparathyroidism
|